China Cell And Gene Therapy Clinical Trials Market Size & Outlook
Related Markets
China cell and gene therapy clinical trials market highlights
- The China cell and gene therapy clinical trials market generated a revenue of USD 573.6 million in 2024 and is expected to reach USD 2,920.3 million by 2033.
- The China market is expected to grow at a CAGR of 20% from 2025 to 2033.
- In terms of segment, phase iii was the largest revenue generating phase in 2024.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy clinical trials market data book summary
| Market revenue in 2024 | USD 573.6 million |
| Market revenue in 2033 | USD 2,920.3 million |
| Growth rate | 20% (CAGR from 2025 to 2033) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
Other key industry trends
- In terms of revenue, China accounted for 5.3% of the global cell and gene therapy clinical trials market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China cell and gene therapy clinical trials market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,920.3 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy Clinical Trials Market Scope
Cell And Gene Therapy Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novotech | View profile | 1001-5000 | Sydney, New South Wales, Australia, Oceania | http://www.novotech-cro.com/ |
| Syneos Health | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | https://www.syneoshealth.com/ |
| Veristat | View profile | 501-1000 | London, England, United Kingdom, Europe | http://www.veristat.com |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | http://www.parexel.com |
| IQVIA Holdings Inc | View profile | 87000 | 2400 Ellis Road, Durham, NC, United States, 27703 | https://www.iqvia.com |
| Medpace Holdings Inc | View profile | 5800 | 5375 Medpace Way, Cincinnati, OH, United States, 45227 | https://www.medpace.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
China cell and gene therapy clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 64.59% in 2024. Horizon Databook has segmented the China cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2021 to 2033.
China is also a lucrative market for cell and gene therapy clinical trials owing to the government initiatives to regulate the cell and gene therapy clinical trials as per the global standards and better infrastructure, which includes 4,000 hospital beds. Initially in China, CDE was responsible was regulating the cell and gene therapy clinical trials.
Realizing the potential of the CRO market and the need for regulating cell and gene therapy clinical trials as per the global standards, in 2013, a new body by combining six regulatory systems were formed. They named it as China Food and Drug Administration (CFDA). CR Medicon, a China-based CRO, states that China is a preferred country for conducting clinical trials due to high recruitment rate of patients.
It states that several pharmaceutical companies have achieved patient recruitment milestones in the country for conducting clinical trials. Although the country has high patient recruitment rates, China lacks advanced infrastructure to support clinical research, which is expected to hinder its market to a certain extent.
Reasons to subscribe to China cell and gene therapy clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China cell and gene therapy clinical trials market databook
-
Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into China cell and gene therapy clinical trials market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
China Phase - Cell And Gene Therapy Clinical Trials Market size, 2024 - 2033 (US$M)
China Cell And Gene Therapy Clinical Trials Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
